Tokyo Tape
Sign in
← Falco Holdings

Quarterly report · Q3

4671.TEDINET S100Q645
Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
MetricValuePeriodScopeSource row
Revenue¥35.9bn2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥50.0bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥36.4bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥2.5bn2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥3.8bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥2.7bn2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥5.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.1bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥2.7bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥4.0bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥1.5bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥3.5bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.5bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥1.5bn2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥2.5bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥38.3bnat 2022-12-31Cons.Assets
Total assets¥40.3bnat 2022-03-31Cons.Assets
Total assets¥38.7bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥13.6bnat 2022-12-31Cons.Liabilities
Total liabilities¥16.8bnat 2022-03-31Cons.Liabilities
Net assets / equity¥24.7bnat 2022-12-31Cons.Net assets
Net assets / equity¥23.5bnat 2022-03-31Cons.Net assets
Net assets / equity¥22.4bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥10.0bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥10.6bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥146.882022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥39.432022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥3392021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥242.322021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥38.082021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥146.232022-04-01 → 2022-12-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥336.992021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥241.232021-04-01 → 2021-12-31Cons.Diluted earnings per share (5-year summary)
Equity ratio64.2%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio58.1%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio57.6%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥6m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥6m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥362m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥23.9bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥23.9bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥5m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥2.3bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥12.0bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥12.0bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥0
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥590m
—segment totalrevenue2022-04-01 → 2022-12-31¥35.9bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥35.9bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥6m
—segment totalsegment profit2022-04-01 → 2022-12-31¥2.9bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥12m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥12m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥279m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥24.2bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥24.2bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥11m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥3.3bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥12.3bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥12.3bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥0
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥770m
—segment totalrevenue2021-04-01 → 2021-12-31¥36.5bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥36.4bn
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥12m
—segment totalsegment profit2021-04-01 → 2021-12-31¥4.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 355
ItemContextValueUnit
Valuation and translation adjustmentsPrior1YearInstant500000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant783000000JPY
Subscription rights to sharesPrior1YearInstant82000000JPY
Subscription rights to sharesCurrentQuarterInstant82000000JPY
Net assetsPrior1YearInstant23478000000JPY
Net assetsCurrentQuarterInstant24691000000JPY
Liabilities and net assetsPrior1YearInstant40256000000JPY
Liabilities and net assetsCurrentQuarterInstant38317000000JPY
Net salesPrior1YTDDuration36441000000JPY
Net salesCurrentYTDDuration35878000000JPY
Cost of salesPrior1YTDDuration24005000000JPY
Cost of salesCurrentYTDDuration24569000000JPY
Gross profitPrior1YTDDuration12435000000JPY
Gross profitCurrentYTDDuration11308000000JPY
Selling general and administrative expensesPrior1YTDDuration8641000000JPY
Selling general and administrative expensesCurrentYTDDuration8798000000JPY
Operating incomePrior1YTDDuration3794000000JPY
Operating incomeCurrentYTDDuration2509000000JPY
Dividends income noiPrior1YTDDuration108000000JPY
Dividends income noiCurrentYTDDuration115000000JPY
Reversal of allowance for doubtful accounts noiPrior1YTDDuration0JPY
Reversal of allowance for doubtful accounts noiCurrentYTDDuration0JPY
Subsidy income noiPrior1YTDDuration133000000JPY
Subsidy income noiCurrentYTDDuration35000000JPY
Other noiPrior1YTDDuration63000000JPY
Other noiCurrentYTDDuration54000000JPY
Non operating incomePrior1YTDDuration305000000JPY
Non operating incomeCurrentYTDDuration205000000JPY
Interest expenses noePrior1YTDDuration21000000JPY
Interest expenses noeCurrentYTDDuration14000000JPY
Commission fee noePrior1YTDDuration4000000JPY
Commission fee noeCurrentYTDDuration4000000JPY
Other noePrior1YTDDuration3000000JPY
Other noeCurrentYTDDuration3000000JPY
Non operating expensesPrior1YTDDuration29000000JPY
Non operating expensesCurrentYTDDuration22000000JPY
Ordinary incomePrior1YTDDuration4071000000JPY
Ordinary incomeCurrentYTDDuration2692000000JPY
Gain on sales of investment securities eiPrior1YTDDuration7000000JPY
Gain on sales of investment securities eiCurrentYTDDuration142000000JPY
Gain on transfer of business eiPrior1YTDDuration15000000JPY
Gain on transfer of business eiCurrentYTDDuration－JPY
Extraordinary incomePrior1YTDDuration22000000JPY
Extraordinary incomeCurrentYTDDuration142000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration0JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration5000000JPY
Loss on valuation of investment securities elPrior1YTDDuration－JPY
Loss on valuation of investment securities elCurrentYTDDuration18000000JPY
Impairment loss elPrior1YTDDuration21000000JPY
Impairment loss elCurrentYTDDuration110000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass